

This week in therapeutics

Indication	Target/marker/pathway	Summary	Licensing status	Publication and contact information
Cancer				
Cancer	Insulin-like growth factor binding protein 2 (IGFBP2)	<p>Mouse studies suggest an N-terminal IGFBP2 vaccine could help treat IGFBP2-overexpressing tumors. In mice with such tumors, a vaccine encoding an epitope of the IGFBP2 N-terminal region induced an antitumor immune response and decreased tumor volume compared with vehicle or vaccines encoding full-length IGFBP2 or a C-terminal epitope. An investigator-led Phase I trial of the vaccine in patients with ovarian cancer is ongoing.</p> <p><i>SciBX 7(23)</i>; doi:10.1038/scibx.2014.673 Published online June 12, 2014</p>	Patent application filed; technology under negotiation for licensing by an undisclosed company; available for licensing	<p>Cecil, D.L. <i>et al. Cancer Res.</i>; published online April 28, 2014; doi:10.1158/0008-5472.CAN-13-3286 Contact: Mary L. Disis, University of Washington, Seattle, Wash. e-mail: ndisis@uw.edu</p>